DelveInsight's "Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pancreatic Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Pancreatic Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Pancreatic Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Pancreatic Cancer: An Overview
Pancreatic cancer is one of the most lethal malignant tumor types, being 4th and 5th leading cause of cancer death in the US and EU, respectively. Advanced/Metastatic pancreatic cancer means cancer has spread from where it started and this process is known as metastasis or has come back sometime after treatment (recurrence) it cannot be cured at this stage but certain treatment options might control it, help symptoms, and improve quality of life for some time. Usually after metastasis, pancreatic cancer spreads to the liver and/or to the lungs.
A clinical/radiographic stage classification for pancreatic cancer suggests a three-stage classification (potentially resectable, locally advanced, and metastatic) of metastatic pancreatic cancer involvement based on radiological findings. The staging system used most often for pancreatic cancer is the AJCC (American Joint Committee on Cancer) TNM system which includes:- the extent of the tumor (T), the spread to nearby lymph nodes (N), the spread (metastasized) to distant sites (M).
Pancreatic Cancer Market Key Facts
-
In 2021, the market size of pancreatic cancer in the US was USD 858 million. Among the EU-5 countries, Germany had the highest market size for pancreatic cancer in 2021, i.e., USD 165 million. The lowest market size was estimated in Spain with USD 61 million in 2021.
-
In Japan, the market size of pancreatic cancer was observed to be USD 270 million in 2021.
-
The United States and Japan account for 52% and 16% respectively of the total market size among the 7MM countries in 2021.
-
Among all the available therapies, in 2021, the highest market was captured by FOLFIRINOX with a market size of USD 569 million, whereas the minimum market capture was by S1 combination therapy in the 7MM.
-
The overall market size of gemcitabine (including monotherapy, and all combinations) in the pancreatic cancer space was USD 625 million in 2021.
-
In 2021, the total incident cases of pancreatic cancer in the 7MM countries were 175,767 cases, and these cases are anticipated to increase during the study period.
-
Among the European countries, Germany had the highest incident cases of pancreatic cancer in 2021, i.e., 21,859 cases, followed by France which had 14,989 incident cases in 2021. On the other hand, Spain had the lowest incident cases of pancreatic cancer, i.e. 8,566 cases in 2021. Japan had 43,170 incident cases of pancreatic cancer in 2021.
-
In terms of stage-specific incident cases, the maximum number of patients were observed for distant pancreatic cancer. This was followed by regional and localized pancreatic cancer.
-
The majority of pancreatic cancer cases are caused by KRAS2 mutation followed by TP53 and SMAD4/DPC4 mutations. The least number of incident cases were observed for pancreatic cancer associated with NTRK mutation.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Pancreatic Cancer pipeline therapies. It also thoroughly assesses the Pancreatic Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Pancreatic Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Pancreatic Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Pancreatic Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Pancreatic Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Pancreatic Cancer Epidemiology, Segmented as -
-
Total Incident cases of pancreatic cancer in the 7MM [2019-2032]
-
Stage-wise cases of pancreatic cancer in the 7MM [2019-2032]
-
Gender-specific cases of pancreatic cancer in the 7MM [2019-2032]
-
Treatable cases of pancreatic cancer in the 7MM [2019-2032]
Pancreatic Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Pancreatic Cancer market or expected to be launched during the study period. The analysis covers the Pancreatic Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Pancreatic Cancer drugs based on their sale and market share.
The report also covers the Pancreatic Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Pancreatic Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Pancreatic Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/pancreatic-cancer-market
Pancreatic Cancer Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Pancreatic Cancer. Currently, Novartis is leading the therapeutics market with its Pancreatic Cancer drug candidates in the most advanced stage of clinical development.
Pancreatic Cancer Companies Actively Working in the Therapeutics Market Include
ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc, ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and many others.
Emerging and Marketed Pancreatic Cancer Therapies Covered in the Report Include:
-
NIS793: Novartis AG
-
Devimistat: Cornerstone Pharmaceuticals
-
Masitinib: AB Science
-
SBP-101: Panbela Therapeutics
-
TAS-102: Taiho Pharmaceutical Co., Ltd.
-
RAIN-32: Rain Oncology
-
IMX-110: Immix Biopharma
And many more
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/pancreatic-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Pancreatic Cancer Competitive Intelligence Analysis
4. Pancreatic Cancer Market Overview at a Glance
5. Pancreatic Cancer Disease Background and Overview
6. Pancreatic Cancer Patient Journey
7. Pancreatic Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Pancreatic Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Pancreatic Cancer Unmet Needs
10. Key Endpoints of Pancreatic Cancer Treatment
11. Pancreatic Cancer Marketed Therapies
12. Pancreatic Cancer Emerging Drugs and Latest Therapeutic Advances
13. Pancreatic Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Pancreatic Cancer Market Outlook (In US, EU5, and Japan)
16. Pancreatic Cancer Companies Active in the Market
17. Pancreatic Cancer Access and Reimbursement Overview
18. KOL Views on the Pancreatic Cancer Market
19. Pancreatic Cancer Market Drivers
20. Pancreatic Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/pancreatic-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
"Narcolepsy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Narcolepsy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Narcolepsy market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
